- Sweeping Vietnam internet law comes into force
- Pope kicks off Christmas under shadow of war
- Catholics hold muted Christmas mass in Indonesia's Sharia stronghold
- Japan's top diplomat in China to address 'challenges'
- Thousands attend Christmas charity dinner in Buenos Aires
- Demand for Japanese content booms post 'Shogun'
- As India's Bollywood shifts, stars and snappers click
- Mystery drones won't interfere with Santa's work: US tracker
- Djokovic eyes more Slam glory as Swiatek returns under doping cloud
- Australia's in-form Head confirmed fit for Boxing Day Test
- Brazilian midfielder Oscar returns to Sao Paulo
- 'Wemby' and 'Ant-Man' to make NBA Christmas debuts
- US agency focused on foreign disinformation shuts down
- On Christmas Eve, Pope Francis launches holy Jubilee year
- 'Like a dream': AFP photographer's return to Syria
- Chiefs seek top seed in holiday test for playoff-bound NFL teams
- Panamanians protest 'public enemy' Trump's canal threat
- Cyclone death toll in Mayotte rises to 39
- Ecuador vice president says Noboa seeking her 'banishment'
- Leicester boss Van Nistelrooy aware of 'bigger picture' as Liverpool await
- Syria authorities say armed groups have agreed to disband
- Maresca expects Man City to be in title hunt as he downplays Chelsea's chancs
- Man Utd boss Amorim vows to stay on course despite Rashford row
- South Africa opt for all-pace attack against Pakistan
- Guardiola adamant Man City slump not all about Haaland
- Global stocks mostly higher in thin pre-Christmas trade
- Bethlehem marks sombre Christmas under shadow of war
- NASA probe makes closest ever pass by the Sun
- 11 killed in blast at Turkey explosives plant
- Indonesia considers parole for ex-terror chiefs: official
- Global stocks mostly rise in thin pre-Christmas trade
- Postecoglou says Spurs 'need to reinforce' in transfer window
- Le Pen says days of new French govt numbered
- Global stocks mostly rise after US tech rally
- Villa boss Emery set for 'very difficult' clash with Newcastle
- Investors swoop in to save German flying taxi startup
- How Finnish youth learn to spot disinformation
- South Korean opposition postpones decision to impeach acting president
- 12 killed in blast at Turkey explosives plant
- Panama leaders past and present reject Trump's threat of Canal takeover
- Hong Kong police issue fresh bounties for activists overseas
- Saving the mysterious African manatee at Cameroon hotspot
- India consider second spinner for Boxing Day Test
- London wall illuminates Covid's enduring pain at Christmas
- Poyet appointed manager at South Korea's Jeonbuk
- South Korea's opposition vows to impeach acting president
- The tsunami detection buoys safeguarding lives in Thailand
- Teen Konstas to open for Australia in Boxing Day India Test
- Asian stocks mostly up after US tech rally
- US panel could not reach consensus on US-Japan steel deal: Nippon
WHO pushes two Ebola treatments found to boost survival rates
The World Health Organization said Friday that two existing treatments dramatically reduced deaths from Ebola and should be given to people of all ages suffering from the often-fatal haemorrhagic disease.
Publishing its first-ever guidelines on which therapeutics to use against Ebola, the UN health agency strongly recommended using two monoclonal antibodies, mAb114, also known as Ansuvimab or Ebanga, and REGN-EB3, or Inmazeb.
Studies had showed that the two treatments significantly "reduced mortality," Janet Diaz, lead of the clinical management unit in the WHO's Health Emergencies programme, told reporters in Geneva.
Depending on the standard of care, she said they could save between 230 and 400 lives for every 1,000 people infected.
In its guidelines, the WHO recommended against using other therapeutics that have been tested for Ebola, including monoclonal antibody ZMapp and antiviral drug remdesivir.
Ebola is an often-fatal viral haemorrhagic fever that was first identified in central Africa in 1976. The disease was named after a river in the Democratic Republic of Congo, then known as Zaire.
The worst epidemic in West Africa between 2013 and 2016 killed more than 11,300 people. The DRC has had more than a dozen epidemics, the deadliest killing 2,280 people in 2020.
Case fatality rates for the disease, which spreads through bodily fluids and causes high fever, vomiting and bleeding, can be as high as 80-90 percent, depending on how quickly it is detected and treated.
The WHO said mAb114 and REGN-EB3 should be given swiftly to anyone who contracts the virus.
In a statement the health agency said that the two had "demonstrated clear benefits" and could be used for everyone infected by Ebola, including older people, pregnant and breastfeeding women, children and newborns.
"Patients should receive recommended neutralising monoclonal antibodies as soon as possible after laboratory confirmation of diagnosis," it said.
The WHO cautioned though that access to both the treatments remained "challenging, especially in resource-poor areas."
"WHO is ready to support countries, manufacturers and partners to improve access to these treatments, and to support national and global efforts to increase affordability," the UN health agency said.
Robert Fowler of the University of Toronto, who co-chaired the guideline development group, hailed how "advances in supportive care and therapeutics over the past decade have revolutionised the treatment of Ebola."
"Ebola virus disease used to be perceived as a near certain killer. However, that is no longer the case," he said in the statement.
Combined with proper support, the two recommended treatments mean "recovery for the vast majority of people," he said.
O.Johnson--AMWN